"Kallikreins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
| Descriptor ID |
D007610
|
| MeSH Number(s) |
D08.811.277.656.300.760.442 D08.811.277.656.959.350.442 D12.776.124.125.597 D23.119.597
|
| Concept/Terms |
Kallikreins- Kallikreins
- Kalliginogenase
- Kallikrein
- Kininogenase
- Callicrein
- Kallidinogenase
- Kinin-Forming Enzyme
- Enzyme, Kinin-Forming
- Kinin Forming Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Kallikreins".
Below are MeSH descriptors whose meaning is more specific than "Kallikreins".
This graph shows the total number of publications written about "Kallikreins" by people in this website by year, and whether "Kallikreins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 2 | 3 | 5 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Kallikreins" by people in Profiles.
-
Genome-wide association study identifies kallikrein 5 in type 2 inflammation-low asthma. J Allergy Clin Immunol. 2022 10; 150(4):972-978.e7.
-
Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation. Gastroenterology. 2022 02; 162(2):521-534.e8.
-
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer. Cells. 2020 09 17; 9(9).
-
Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Cancer. 2020 12 01; 126(23):5114-5123.
-
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041.
-
Editorial Comment. J Urol. 2020 08; 204(2):287.
-
Racial disparity in the utilization of multiparametric MRI-ultrasound fusion biopsy for the detection of prostate cancer. Prostate Cancer Prostatic Dis. 2020 12; 23(4):567-572.
-
Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020 Apr; 203(4):706-712.
-
Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264.
-
Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients. Prostate. 2019 02; 79(3):259-264.